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Patients with symptoms of possible acute coronary 
syndrome make up a large proportion of people who 
present to emergency departments, where they undergo 
lengthy, intensive, and costly assessments.1,2 Yet few 
are ﬁ nally diagnosed with an acute coronary syndrome. 
Improvements in methods to exclude acute coronary 
syndrome are needed to reliably reassure and safely 
discharge low-risk patients who can then proceed to 
further investigations as outpatients. High-sensitivity 
cardiac troponin assays are reliable and have low 
thresholds of detection. But how to take full advantage 
of this improved precision in clinical care is unclear.3–5
In The Lancet, Anoop Shah and colleagues6 report 
results of a prospective observational cohort study of 
6304 patients presenting at emergency departments 
with suspected acute coronary syndrome. They 
identiﬁ ed a threshold for a high-sensitivity cardiac 
troponin assay below which patients were at low risk of 
type 1 myocardial infarction and potentially suitable for 
early discharge from hospital. The primary outcome was 
index myocardial infarction, or subsequent myocardial 
infarction or cardiac death at 30 days. The investigators 
derived 5 ng/L as the optimum cutoﬀ  for cardiac 
troponin I concentration, using a predeﬁ ned negative 
predictive value of 99·5% as an acceptable threshold of 
safety. This threshold enabled a large proportion of the 
total patients presenting to emergency departments 
(2311 [47%] of 4870) assessed for possible myocardial 
infarction to be identiﬁ ed on presentation as at low 
risk for events at presentation and at 30 days. For those 
patients who were not identiﬁ ed as having a myocardial 
infarction on presentation (2311 [61%] of 3799), this 
threshold had a negative predictive value of 99·6% 
(95% CI 99·4–99·9). The results were validated in two 
cohorts of 1434 patients presenting to emergency 
departments with similar positive ﬁ ndings (overall 
negative predictive value 99·4%, 95% CI 98·8–99·9). 
The negative predictive value, although an accepted 
method of evaluating screening tests of exclusion, 
is aﬀ ected by disease prevalence, and this should 
be considered in diﬀ erent emergency department 
populations.
These ﬁ ndings are highly promising. The 
investigators identiﬁ ed some aspects of clinical 
practice that might have aﬀ ected the ﬁ ndings. Fewer 
than 42% (1608 of 3799) patients had serial troponin 
testing despite guideline recommendations.7,8 Patients 
with a delayed increase in troponin after the initial 
test might therefore not have been identiﬁ ed as 
having an acute myocardial infarction, and missed 
events might be more common than reported. 
Furthermore, the median time for the single troponin 
test was 54 min (IQR 33–85) after presentation to the 
emergency department. In systems that support very 
early blood sampling in the emergency department, 
the threshold of 5 ng/L might not have such a high 
negative predictive value. In addition, although early 
presenters represent only a small proportion of all 
patients (5%), the use of the single troponin test value 
failed to meet the predeﬁ ned negative predictive value 
of 99·5% in these patients, and serial testing should 
continue in such patients.
Additionally, there are important considerations 
relating to troponin assays when interpreting (and 
considering implementation of) the ﬁ ndings of this 
study. First, all troponin assays are diﬀ erent, and the 
cutoﬀ  and ﬁ ndings described by Shah and colleagues6 
are speciﬁ c to the troponin assay that they used. These 
do not apply to any other assays, even other high-
sensitivity assays.9
Second, high-sensitivity cardiac troponin assays 
provide improved analytical precision at low 
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With the emergence of eﬀ ective treatments for 
inﬂ ammatory arthritis, the new concept of treat to 
target has evolved. Treat to target is deﬁ ned as “a 
treatment strategy in which the clinician treats the 
patient aggressively enough to reach and maintain 
explicitly speciﬁ ed and sequentially measured goals, 
such as remission or low disease activity”.1 A proactive 
clear endpoint, which is the aim of the tre atment, should 
be used as a speciﬁ c target algorithm. This endpoint 
should be supported by ﬁ ndings from randomised 
controlled trials which suggest that early aggressive 
treatment approaches are advantageous. In rheumatoid 
arthritis, this treatment approach has been proven to be 
eﬀ ective in the Tight Control of Rheumatoid Arthritis 
(TICORA) trial.2 Indeed, an international task force has 
now published treat-to-target recommendations for 
rheumatoid arthritis.3
In psoriatic arthritis—an inﬂ ammatory 
musculoskeletal disease associated with psoriasis—
ascertainment of the treatment target has been more 
Is it time for treat to target in psoriatic arthritis?
concentrations of troponin compared with previous 
generations. Clinicians should be aware that results 
are usually less reliable at troponin concentrations 
lower than at the 99th percentile.9 To be classiﬁ ed as 
high sensitivity, an assay must have a coeﬃ  cient of 
variation of at least 10% at the 99th percentile for 
the assay. When considering local implementation of 
this diagnostic strategy, the assay’s precision should 
be discussed by the laboratory and clinicians (eg, 
specialists in emergency medicine, cardiology, and 
internal medicine) with an assessment made about the 
ability to maintain acceptable precision. Reassuringly, 
in this study,6 the interlaboratory precision across 
33 instruments at 3·5 ng/L was good, suggesting that 
the accuracy of this assay in clinical practice might 
be reliable. The ultimate validation for the safety and 
eﬃ  cacy of discharging patients with cardiac troponin 
concentrations less than 5 ng/L will be the report of 
clinical outcomes after this threshold is implemented in 
routine clinical practice.
Finally, what further assessment, if any, is needed for 
those patients identiﬁ ed as low risk and suitable for 
early discharge? Trials are needed to assess the safety 
and eﬀ ectiveness of clinical pathways that involve no 
further testing for such patients.
Shah and colleagues’ study6 is a huge advance in the 
assessment of patients with possible acute coronary 
syndrome in emergency departments. We strongly 
urge close collaboration between front-line clinicians 
and their laboratory colleagues to identify optimum 
assessment strategies, including consideration of 
troponin assay availability and reliability, before local 
implementation.
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